Experienced in Desmoid Tumor

Chaosu Q. Hu

4365 Kangxin Road, 
Shanghai, CN 
Experienced in Desmoid Tumor
4365 Kangxin Road, 
Shanghai, CN 
OverviewLocationsClinical Research

Overview

Chaosu Hu practices in Shanghai, China. Hu is rated as an Experienced expert by MediFind in the treatment of Desmoid Tumor. Their top areas of expertise are Nasopharyngeal Carcinoma, Head and Neck Squamous Cell Carcinoma (HNSCC), Dry Mouth, Tongue Cancer, and Laryngectomy.

Their clinical research consists of co-authoring 179 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 2 articles in the study of Desmoid Tumor.

Locations

4365 Kangxin Road, Shanghai, 201315, China
Other Locations
China P.R, Wuhan, 430070, China
138 Yixueyuan Road, Shanghai, 200032, China
No.182, Tongguan Road, Lianyungang, 222002, China
270 Dong An Road, Shanghai, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)
Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)
Enrollment Status: Active_not_recruiting
Publish Date: November 19, 2025
Intervention Type: Other, Drug, Radiation
Study Drugs: Cisplatin, Fluorouracil, Gemcitabine Hydrochloride, Paclitaxel
Study Phase: Phase 2/Phase 3
A Phase III, Randomized, Placebo Controlled, Multicenter, Double-Blind Study Comparing Toripalimab Injection (JS001) Combined With Chemotherapy Versus Placebo Combined With Chemotherapy for Recurrent or Metastatic Nasopharyngeal Cancer
A Phase III, Randomized, Placebo Controlled, Multicenter, Double-Blind Study Comparing Toripalimab Injection (JS001) Combined With Chemotherapy Versus Placebo Combined With Chemotherapy for Recurrent or Metastatic Nasopharyngeal Cancer
Enrollment Status: Completed
Publish Date: September 02, 2025
Intervention Type: Drug, Biological
Study Phase: Phase 3
A Randomized, Double-blind, Multi-center Phase III Study of Penpulimab (AK105) Combined With Chemotherapy Versus Placebo Combined With Chemotherapy in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma
A Randomized, Double-blind, Multi-center Phase III Study of Penpulimab (AK105) Combined With Chemotherapy Versus Placebo Combined With Chemotherapy in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2025
Intervention Type: Drug
Study Drug: Penpulimab
Study Phase: Phase 3
Phase II Study of Comparing Toripalimab Combined With GP Regimen Chemotherapy Versus GP Regimen Chemotherapy for Primary Metastatic Nasopharyngeal Carcinoma
Phase II Study of Comparing Toripalimab Combined With GP Regimen Chemotherapy Versus GP Regimen Chemotherapy for Primary Metastatic Nasopharyngeal Carcinoma
Enrollment Status: Active_not_recruiting
Publish Date: April 02, 2025
Intervention Type: Drug, Radiation
Study Drugs: Toripalimab, Gemcitabine+Cisplatin Chemotherapy, Adjuvant chemotherapy with Capecitabine
Study Phase: Phase 2
A Single-arm, Open-label, Multicenter Phase II Clinical Study of AK105 in Patients With Metastatic Nasopharyngeal Carcinoma After Failure of Second and Subsequent Lines of Chemotherapy
A Single-arm, Open-label, Multicenter Phase II Clinical Study of AK105 in Patients With Metastatic Nasopharyngeal Carcinoma After Failure of Second and Subsequent Lines of Chemotherapy
Enrollment Status: Completed
Publish Date: February 27, 2025
Intervention Type: Biological
Study Drug: AK105
Study Phase: Phase 2
Phase Ⅲ Study of Neoadjuvant TPF Chemotherapy Followed by Radiotherapy With Concurrent Nimotuzumab or Cisplatin for Locoregionally Advanced Nasopharyngeal Carcinoma (NPC).
Phase Ⅲ Study of Neoadjuvant TPF Chemotherapy Followed by Radiotherapy With Concurrent Nimotuzumab or Cisplatin for Locoregionally Advanced Nasopharyngeal Carcinoma (NPC).
Enrollment Status: Completed
Publish Date: April 10, 2019
Intervention Type: Radiation, Drug
Study Phase: Phase 3
View 5 Less Clinical Trials

179 Total Publications

Expert consensus on the combination of Anti-EGFR monoclonal antibodies and immune checkpoint inhibitors in the treatment of head and neck squamous cell carcinoma.
Expert consensus on the combination of Anti-EGFR monoclonal antibodies and immune checkpoint inhibitors in the treatment of head and neck squamous cell carcinoma.
Journal: Cancer treatment reviews
Published: September 08, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Hu's expertise for a condition
ConditionClose
    View All 17 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile